Shi Yao Holding Group Co., Ltd. was established in 1997. Under the concept of "making good medicine, serving China and contributing to the world", through innovation and development, its main business indicators have maintained double-digit growth for many years. Now it has developed into an international innovative enterprise with 28,000 employees. Its Hong Kong listed company (0 1093. HK) was selected as a constituent stock of Hang Seng Index, and on behalf of China Pharmaceutical, it was selected as the 23rd in the ranking of R&D pipeline scale of global pharmaceutical companies, serving patients all over the world.
Innovative drugs such as Enbipu, Mingfule, Duoenyi, Jinlitai, Haitan, Duoenda and Ouyuexin. Enbip, Xuanning and Jin Youli all won the second prize of National Science and Technology Progress Award, which is the highest national award in the field of medicine. In 2023, 1 new drug from two countries will be listed: Naxorubizumab injection (the world's first IgG4 RANKL inhibitor) and gumitinib tablets (global independent intellectual property rights). The Group has also built a global industrial chain through raw materials that account for an absolute share of the international market, ensuring the safety and stability of the international pharmaceutical industrial chain.